Emily Curran

1.4k total citations
42 papers, 765 citations indexed

About

Emily Curran is a scholar working on Public Health, Environmental and Occupational Health, Hematology and Oncology. According to data from OpenAlex, Emily Curran has authored 42 papers receiving a total of 765 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Public Health, Environmental and Occupational Health, 17 papers in Hematology and 13 papers in Oncology. Recurrent topics in Emily Curran's work include Acute Lymphoblastic Leukemia research (16 papers), Acute Myeloid Leukemia Research (9 papers) and Childhood Cancer Survivors' Quality of Life (8 papers). Emily Curran is often cited by papers focused on Acute Lymphoblastic Leukemia research (16 papers), Acute Myeloid Leukemia Research (9 papers) and Childhood Cancer Survivors' Quality of Life (8 papers). Emily Curran collaborates with scholars based in United States, Canada and Chile. Emily Curran's co-authors include Wendy Stock, Justin Kline, Leticia Corrales, James Godfrey, Thomas W. Dubensky, Priyanka Duttagupta, Marcin Kortylewski, Douglas E. Kline, Sonali M. Smith and Xiufen Chen and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

Emily Curran

40 papers receiving 760 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
Emily Curran United States 16 278 263 220 201 194 42 765
Cristina Bugarin Italy 13 153 0.6× 197 0.7× 273 1.2× 142 0.7× 161 0.8× 26 605
Valentina Gianfelici Italy 15 243 0.9× 113 0.4× 312 1.4× 168 0.8× 280 1.4× 29 736
Maria Cristina Rapanotti Italy 14 171 0.6× 144 0.5× 313 1.4× 163 0.8× 170 0.9× 28 598
Axel Schulenburg Austria 18 235 0.8× 216 0.8× 511 2.3× 337 1.7× 86 0.4× 41 990
Mahasweta Gooptu United States 16 123 0.4× 192 0.7× 432 2.0× 201 1.0× 103 0.5× 66 683
Susana Vives Spain 10 272 1.0× 76 0.3× 533 2.4× 209 1.0× 231 1.2× 37 791
Simona Lapusan France 15 146 0.5× 109 0.4× 350 1.6× 271 1.3× 124 0.6× 33 676
O. J. H. M. Verhagen Netherlands 13 128 0.5× 157 0.6× 219 1.0× 108 0.5× 112 0.6× 25 494
Prashant Tembhare India 17 233 0.8× 180 0.7× 438 2.0× 300 1.5× 296 1.5× 97 909
Lisa Pleyer Austria 18 369 1.3× 204 0.8× 435 2.0× 248 1.2× 115 0.6× 53 947

Countries citing papers authored by Emily Curran

Since Specialization
Citations

This map shows the geographic impact of Emily Curran's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Emily Curran with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Emily Curran more than expected).

Fields of papers citing papers by Emily Curran

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Emily Curran. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Emily Curran. The network helps show where Emily Curran may publish in the future.

Co-authorship network of co-authors of Emily Curran

This figure shows the co-authorship network connecting the top 25 collaborators of Emily Curran. A scholar is included among the top collaborators of Emily Curran based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Emily Curran. Emily Curran is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Luskin, Marlise R., Jun Yin, Gerard Lozanski, et al.. (2025). Alemtuzumab in frontline therapy of adult acute lymphoblastic leukemia: Results of Cancer and Leukemia Group B 10102 (Alliance), a phase 1/2 study. Cancer. 131(4). e35750–e35750. 2 indexed citations
3.
4.
Curran, Emily, et al.. (2022). P-65 A hospice virtual ward – Providing complex palliative care in the community. Poster presentations. A34.3–A35. 1 indexed citations
5.
6.
Grover, Punita, et al.. (2021). CT-436: Chimeric Antigen Receptor T-Cell Therapy (CAR-T) in Adults with B-Cell Acute Lymphoblastic Leukemia (B-ALL): A Systematic Review and Meta-Analysis. Clinical Lymphoma Myeloma & Leukemia. 21. S454–S454. 1 indexed citations
7.
Curran, Emily & Maureen M. O’Brien. (2020). Role of blinatumomab, inotuzumab, and CAR T-cells: Which to choose and how to sequence for patients with relapsed disease. Seminars in Hematology. 57(3). 157–163. 10 indexed citations
8.
Wang, Amy, Howard Weiner, Margaret Green, et al.. (2018). A phase I study of selinexor in combination with high-dose cytarabine and mitoxantrone for remission induction in patients with acute myeloid leukemia. Journal of Hematology & Oncology. 11(1). 4–4. 50 indexed citations
9.
Curran, Emily, et al.. (2018). Bayesian Adaptive Design for Finding the Maximum Tolerated Sequence of Doses in Multicycle Dose-Finding Clinical Trials. JCO Precision Oncology. 2(2). 1–19. 6 indexed citations
10.
Curran, Emily, James Godfrey, & Justin Kline. (2017). Mechanisms of Immune Tolerance in Leukemia and Lymphoma. Trends in Immunology. 38(7). 513–525. 73 indexed citations
11.
Curran, Emily, Xiufen Chen, Leticia Corrales, et al.. (2016). STING Pathway Activation Stimulates Potent Immunity against Acute Myeloid Leukemia. Cell Reports. 15(11). 2357–2366. 141 indexed citations
12.
Yap, Kai Lee, Larissa V. Furtado, Kazuma Kiyotani, et al.. (2016). Diagnostic evaluation of RNA sequencing for the detection of genetic abnormalities associated with Ph-like acute lymphoblastic leukemia (ALL). Leukemia & lymphoma. 58(4). 950–958. 16 indexed citations
13.
Curran, Emily, Leticia Corrales, & Justin Kline. (2015). Targeting the Innate Immune System as Immunotherapy for Acute Myeloid Leukemia. Frontiers in Oncology. 5. 83–83. 31 indexed citations
14.
Curran, Emily & Wendy Stock. (2015). How I treat acute lymphoblastic leukemia in older adolescents and young adults. Blood. 125(24). 3702–3710. 92 indexed citations
15.
Curran, Emily & Sonali M. Smith. (2014). Phosphoinositide 3-kinase inhibitors in lymphoma. Current Opinion in Oncology. 26(5). 469–475. 32 indexed citations
16.
Curran, Emily, Xiufen Chen, Leticia Corrales, & Justin Kline. (2014). Activation of the Sting Pathway Enhances Immunity and Improves Survival in a Murine Myeloid Leukemia Model. Blood. 124(21). 3759–3759. 1 indexed citations
17.
Maggiore, Ronald J., Emily Curran, Mary Ellyn Witt, et al.. (2013). Survival and selected outcomes of older adults with locally advanced head/neck cancer treated with chemoradiation therapy. Journal of Geriatric Oncology. 4(4). 327–333. 29 indexed citations
18.
Jain, Nitin, Emily Curran, Neil M. Iyengar, et al.. (2012). Phase II study of the oral MEK inhibitor selumetinib (AZD6244) in advanced acute myeloid leukemia (AML).. Journal of Clinical Oncology. 30(15_suppl). 6582–6582. 6 indexed citations
19.
Partap, Sonia, Emily Curran, Jennifer M. Propp, et al.. (2009). Medulloblastoma Incidence has not Changed Over Time. Journal of Pediatric Hematology/Oncology. 31(12). 970–971. 22 indexed citations
20.
Curran, Emily, Kristin L. Sainani, Gem M. Le, Jennifer M. Propp, & Paul G. Fisher. (2008). Gender affects survival for medulloblastoma only in older children and adults: A study from the surveillance epidemiology and end results registry. Pediatric Blood & Cancer. 52(1). 60–64. 31 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Cristina Bugarin Breakdown of academic impact, for papers by Valentina Gianfelici Breakdown of academic impact, for papers by Maria Cristina Rapanotti Breakdown of academic impact, for papers by Axel Schulenburg Breakdown of academic impact, for papers by Mahasweta Gooptu Breakdown of academic impact, for papers by Susana Vives Breakdown of academic impact, for papers by Simona Lapusan Breakdown of academic impact, for papers by O. J. H. M. Verhagen Breakdown of academic impact, for papers by Prashant Tembhare Breakdown of academic impact, for papers by Lisa Pleyer
Rankless by CCL
2026